文献速递冠心病血脂与心血管预防

载脂蛋白AI位点特异性糖基化损害HDL功能并促进糖尿病动脉粥样硬化

Site-Specific Apo AI Glycation Impairs HDL Function and Promotes Atherosclerosis in Diabetes.
PubMed 文献 · Circulation · 2026-08-25

该研究对860例2型糖尿病合并冠状动脉粥样硬化(CAS)患者和294例无CAS的2型糖尿病对照进行位点分辨糖基化蛋白质组学分析,发现载脂蛋白AI(apo AI)糖基化模式在两组间存在差异,K96和K106/107为突出的疾病相关糖基化位点。研究构建的Apo AI糖基化指数与CAS独立相关,并与HDL介导的逆向胆固醇转运及卵磷脂胆固醇酰基转移酶活性呈负相关。机制上,糖基化apo AI通过RAGE-ERK1/2-NF-κB/p65信号上调NR2C2,抑制LXRα活性,损害巨噬细胞胆固醇外流;耐糖基化apo AI突变体(apo AICL)在临床前模型中保留HDL功能并减轻动脉粥样硬化。

要点

  • apo AI糖基化位点K96和K106/107与2型糖尿病合并CAS相关。
  • Apo AI糖基化指数与CAS独立相关,并与HDL逆向胆固醇转运负相关。
  • 耐糖基化apo AICL在糖尿病小鼠中减轻HDL功能障碍和动脉粥样硬化病变。

核心结论

  • 本研究提供了糖尿病患者apo AI糖基化的位点分辨图谱,并确定Apo AI糖基化指数是与糖尿病CAS和HDL功能受损相关的糖基化特征。
  • 实验数据支持位点特异性apo AI糖基化通过RAGE相关的NR2C2-LXRα信号促进HDL功能障碍和巨噬细胞胆固醇外流受损的机制。
  • 耐糖基化apo AICL在临床前模型中保留HDL功能并减轻动脉粥样硬化,支持位点特异性apo AI糖基化作为糖尿病动脉粥样硬化机制相关特征。

研究设计与样本

  • 对860例2型糖尿病合并冠状动脉粥样硬化(CAS)患者和294例无CAS的2型糖尿病对照进行无偏位点分辨糖基化蛋白质组学分析。
  • 使用无监督和有监督整合分析识别与糖尿病CAS相关的apo AI糖基化特征,并用LASSO回归构建Apo AI糖基化指数,在训练、测试和独立验证队列中评估。
  • 工程化耐糖基化apo AI突变体(交联apo AI,apo AICL),在糖基化条件下通过表面等离子共振、体外和体内逆向胆固醇转运实验、HDL重塑分析及动脉粥样硬化模型进行功能验证。
  • 采用RNA测序、巨噬细胞特异性敲除模型、受体结合实验、信号抑制和胆固醇外流救援实验探究巨噬细胞通路。

主要发现

  • 2型糖尿病合并CAS与不合并CAS的患者apo AI糖基化模式不同,K96和K106/107为突出的疾病相关糖基化位点。
  • Apo AI糖基化指数在2型糖尿病患者中与CAS和冠状动脉疾病独立相关,并与HDL介导的逆向胆固醇转运及卵磷脂胆固醇酰基转移酶活性呈负相关。
  • 与天然apo AI相比,apo AICL在糖基化条件下关键位点糖基化减少、结构稳定性保留、与卵磷脂胆固醇酰基转移酶结合亲和力增强,并改善HDL介导的逆向胆固醇转运。
  • 在糖尿病小鼠模型中,与糖基化apo AI相比,apo AICL减轻HDL功能障碍和动脉粥样硬化病变形成。
  • 糖基化apo AI增强RAGE相互作用并激活ERK1/2-NF-κB/p65信号,上调NR2C2;LXRα激活和巨噬细胞NR2C2缺陷可恢复糖基化apo AI处理巨噬细胞的胆固醇外流。

临床怎么用

  • Apo AI糖基化指数或可作为识别2型糖尿病合并冠状动脉粥样硬化及HDL功能受损患者的候选生物标志物。
  • 靶向apo AI特定位点糖基化(如K96和K106/107)或RAGE-NR2C2-LXRα通路可能成为改善糖尿病动脉粥样硬化的策略。
  • 耐糖基化apo AICL在临床前模型中显示保护作用,支持进一步临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Apo (apolipoprotein) AI glycation has been implicated in HDL (high-density lipoprotein) dysfunction, but its site-resolved landscape, clinical relevance, relationship with diabetic atherosclerosis, and underlying mechanisms remain incompletely defined. METHODS: We performed unbiased site-resolved glycation proteomics in 860 patients with type 2 diabetes and coronary atherosclerosis (CAS) and 294 controls with type 2 diabetes without CAS to define the plasma apo AI glycation landscape. Apo AI glycation signatures associated with diabetic CAS were identified using integrated unsupervised and supervised analyses. An Apo AI Glycation Index was developed using least absolute shrinkage and selection operator regression and evaluated in training, testing, and independent validation cohorts. To assess functional relevance, a glycation-resistant apo AI mutant, cross-linked apo AI (apo AICL), was engineered and tested under glycation conditions using surface plasmon resonance, in vitro and in vivo reverse cholesterol transport assays, HDL remodeling analyses, and atherosclerosis models. RNA sequencing, macrophage-specific knockout models, receptor-binding assays, signaling inhibition, and cholesterol efflux rescue experiments were used to investigate the underlying macrophage pathway. RESULTS: Apo AI glycation patterns differed between patients with type 2 diabetes with and without CAS, with K96 and K106/107 emerging as prominent disease-associated glycation sites. The Apo AI Glycation Index was independently associated with CAS and coronary artery disease in patients with type 2 diabetes and was inversely associated with HDL-mediated reverse cholesterol transport and lecithin-cholesterol acyltransferase activity. Compared with native apo AI, apo AICL showed reduced key-site glycation, preserved structural stability, enhanced binding affinity to lecithin-cholesterol acyltransferase, and improved HDL-mediated reverse cholesterol transport under glycation conditions. In diabetic mouse models, apo AICL attenuated HDL dysfunction and atherosclerotic lesion formation compared with glycated apo AI. These data support a candidate mechanism in which glycated apo AI enhances RAGE (receptor for advanced glycation end products) interaction and activates ERK1/2 (extracellular signal-regulated kinase 1/2)-NF-κB (nuclear factor κB)/p65 signaling, leading to upregulation of NR2C2 (nuclear receptor subfamily 2 group C member 2). LXRα (liver X receptor α) activation and macrophage NR2C2 deficiency restored cholesterol efflux in glycated apo AI-treated macrophages. CONCLUSIONS: This study provides a comprehensive site-resolved map of apo AI glycation in patients with diabetes and identifies the Apo AI Glycation Index as a glycation signature associated with diabetic CAS and impaired HDL function. Experimental data support a mechanism in which site-specific apo AI glycation contributes to HDL dysfunction and macrophage cholesterol efflux impairment through RAGE-associated NR2C2-LXRα signaling. Glycation-resistant apo AICL preserves HDL function and attenuates atherosclerosis in preclinical models, supporting site-specific apo AI glycation as a mechanistically relevant feature of diabetic atherosclerosis. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05659043.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Dai Y, Li Q, Ding F, et al. Site-Specific Apo AI Glycation Impairs HDL Function and Promotes Atherosclerosis in Diabetes. Circulation. 2026. PMID: 42639673. doi:10.1161/CIRCULATIONAHA.125.078171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。